

CDK1/CDC2 (Phospho-Thr161) Antibody

Catalog No: #12493



Package Size: #12493-1 50ul #12493-2 100ul

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com


Description

Product Name	CDK1/CDC2 (Phospho-Thr161) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	WB
Species Reactivity	Hu Ms Rt
Specificity	CDK1/CDC2 (Phospho-Thr161) Antibody detects endogenous levels of CDK1/CDC2 only when phosphorylated at Thr161
Immunogen Type	Peptide
Immunogen Description	A synthesized peptide derived from human CDK1/CDC2 (Phospho-Thr161)
Target Name	CDK1/CDC2
Modification	Phospho
Other Names	CDK1, CDC28A, CDC2, CDKN1, Cyclin-dependent kinase 1, p34 protein kinase, p34CDC2, CDC2a, Cell cycle controller CDC2, Cell division protein kinase 1, PSTAIR
Accession No.	Swiss-Prot#: P06493NCBI Gene ID: 983
Target Species	human
Calculated MW	34kd
Concentration	1.0mg/ml
Formulation	Rabbit IgG in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C

Application Details

Western blotting: 1:1000

Images



Western blot analysis CDK1/CDC2 (Phospho-Thr161) using EGF treated 293 whole cell lysates

Published Papers

el at., Pseudolaric acid B induces mitotic arrest and apoptosis in both imatinib-sensitive and -resistant chronic myeloid leukaemia cells. In Eur J Pharmacol on 2020 Jun 5; by Jiang L, Wen C, et al..PMID: 32179085, , (2020)

[PMID:32179085](#)

el at., Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and-resistant colorectal cancer cells. In Cancer Lett on 2016 Dec 28 by Chuangyu Wen , Junxiong Chen et al..PMID: 27713084, , (2016)

[PMID:27713084](#)

el at., Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. In Curr Cancer Drug Targets on 2012 Jul by

A Matsuhashi, T Ohno, et al..PMID:22463590, , (2012)

[PMID:22463590](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.